Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Tristel ( (GB:TSTL) ).
Tristel reported a strong first half to 31 December 2025, with revenue up 14% to £25.65m, adjusted EBITDA up 17% and adjusted profit before tax up 11%, supported by robust gross margins of 81% and continued cash generation with no debt. The company maintained its interim dividend, grew both UK and overseas sales, and saw particularly strong gains from its medical device and Cache surface product lines.
Growth in the United States was a standout, with US revenues rising more than sixfold on the back of accelerating sales of its ULT ultrasound disinfection product, strong royalty income and updated American clinical guidelines that now endorse chlorine dioxide for high-level disinfection. Tristel also launched its OPH ophthalmic disinfectant in the US, introduced the VISICLEAN cleaning product, completed in-house wipe manufacture and appointed a new CFO, while CEO Matt Sassone confirmed he will step down at year-end, a leadership transition the company says will not derail its strategic trajectory.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £478.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Spark’s Take on GB:TSTL Stock
According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Outperform.
Tristel’s strong financial performance and positive earnings call outlook are the primary drivers of its stock score. While technical indicators suggest caution due to overbought conditions, the company’s strategic expansion and dividend increase support a favorable long-term view. Valuation concerns are mitigated by the company’s growth prospects.
To see Spark’s full report on GB:TSTL stock, click here.
More about Tristel
Tristel plc is a global infection prevention company that manufactures and supplies disinfectant products based on proprietary chlorine dioxide chemistry. It is a market leader in manual decontamination of medical devices and offers a sporicidal surface disinfection range as a sustainable alternative to pre-wetted plastic wipes, operating from its Cambridge-area base across 40+ countries via 16 subsidiaries.
Average Trading Volume: 109,355
Technical Sentiment Signal: Strong Buy
Current Market Cap: £191.7M
For detailed information about TSTL stock, go to TipRanks’ Stock Analysis page.